Interstitial lung disease in connective tissue diseases: Evolving concepts of pathogenesis and management

Flavia V. Castelino*, John Varga

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

77 Scopus citations

Abstract

Interstitial lung disease (ILD) is a challenging clinical entity associated with multiple connective tissue diseases, and is a significant cause of morbidity and mortality. Effective therapies for connective tissue disease-associated interstitial lung disease (CTD-ILD) are still lacking. Multidisciplinary clinics dedicated to the early diagnosis and improved management of patients with CTD-ILD are now being established. There is rapid progress in understanding and identifying the effector cells, the proinflammatory and profibrotic mediators, and the pathways involved in the pathogenesis of CTD-ILD. Serum biomarkers may provide new insights as risk factors for pulmonary fibrosis and as measures of disease progression. Despite these recent advances, the management of patients with CTD-ILD remains suboptimal. Further studies are therefore urgently needed to better understand these conditions, and to develop effective therapeutic interventions.

Original languageEnglish (US)
Article number213
JournalArthritis Research and Therapy
Volume12
Issue number4
DOIs
StatePublished - Aug 23 2010

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Interstitial lung disease in connective tissue diseases: Evolving concepts of pathogenesis and management'. Together they form a unique fingerprint.

Cite this